Castle Creek Biosciences, Inc. (CCBS)
Castle Creek Biosciences is a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options.
Our proprietary platform serves as the foundation for developing personalized, targeted and redosable cell-based gene therapy product candidates. At present, our novel in-house manufacturing process entails collecting minimally invasive skin biopsies from patients, and transducing fibroblast cells with a third-generation self-inactivating lentiviral vector to express a targeted protein of interest.
The genetically modified cells are then intradermally administered to the disease site with the goal of expressing the target protein in the desired region.
As part of this process, we also create a personalized cell bank of genetically modified autologous fibroblasts that can be stored cryogenically, serving as a repository for the patient’s long term drug product needs.
Our most advanced product candidate, D-Fi, is currently in a Phase 3 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa, or RDEB, with topline data expected in the second half of 2022.
We are initially prioritizing our clinical-stage product candidates for skin and connective tissue diseases, with the goal of expanding into other rare diseases and broader indications where patients have limited or no therapeutic options.
405 Eagleview Boulevard
Exton, PA 19341
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Matthew Gantz||President, Chief Executive Officer, Director|
|Mary Spellman, M.D.||Chief Medical Officer, Senior Vice President of Research & Development|
|Gregory Wujek||Chief Commercial Officer|
|Gregory MacMichael, Ph.D.||Chief Technology Officer|
|W. Bradford Middlekauff||Chief Legal Officer|
|Jeffrey S. Aronin||Director, Chairman|
|Antonio J. Gracias||Director|
|R. Mark Graf||Director|